238 related articles for article (PubMed ID: 20414223)
1. A bitter pill.
Nat Chem; 2010 May; 2(5):337. PubMed ID: 20414223
[No Abstract] [Full Text] [Related]
2. Precompetitive research: a new prescription for drug development?
Woodcock J
Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454
[No Abstract] [Full Text] [Related]
3. Buy buy bispecific antibodies.
Holmes D
Nat Rev Drug Discov; 2011 Oct; 10(11):798-800. PubMed ID: 22037028
[No Abstract] [Full Text] [Related]
4. To make better therapeutics, companies strive to increase the content of results and get them faster.
Szpir M
Biotechniques; 2007 Apr; 42(4 Suppl):S3-5. PubMed ID: 18798735
[No Abstract] [Full Text] [Related]
5. Open innovation: share or die..
Talaga P
Drug Discov Today; 2009 Nov; 14(21-22):1003-5. PubMed ID: 19778629
[No Abstract] [Full Text] [Related]
6. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Graul AI; Revel L; Rosa E; Cruces E
Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
[TBL] [Abstract][Full Text] [Related]
7. Discontinued drugs in 2010: oncology drugs.
Williams R
Expert Opin Investig Drugs; 2011 Nov; 20(11):1479-96. PubMed ID: 21955127
[TBL] [Abstract][Full Text] [Related]
8. Can open-source drug R&D repower pharmaceutical innovation?
Munos B
Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458
[TBL] [Abstract][Full Text] [Related]
9. Trends in risks associated with new drug development: success rates for investigational drugs.
DiMasi JA; Feldman L; Seckler A; Wilson A
Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
[TBL] [Abstract][Full Text] [Related]
10. Biomedicine. Pharma firms push for sharing of cancer trial data.
Bhattacharjee Y
Science; 2012 Oct; 338(6103):29. PubMed ID: 23042862
[No Abstract] [Full Text] [Related]
11. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
Hedner T; Gatenbeck L
Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
[No Abstract] [Full Text] [Related]
12. India's drug tests.
Padma TV
Nature; 2005 Jul; 436(7050):485. PubMed ID: 16049471
[No Abstract] [Full Text] [Related]
13. Ask the experts: future of the pharmaceutical industry. Interview by Future Medicinal Chemistry.
Cottens S; Eaton M; Fuhr J; Geary S; Johnson DS; Li G; Raveglia L; Robertson GM; Westwell A
Future Med Chem; 2011 Nov; 3(15):1863-72. PubMed ID: 22023030
[TBL] [Abstract][Full Text] [Related]
14. David Haslam. Interview by Asher Mullard.
Haslam D
Nat Rev Drug Discov; 2013 Jul; 12(7):500. PubMed ID: 23764976
[No Abstract] [Full Text] [Related]
15. Traditional drug-discovery model ripe for reform.
Cressey D
Nature; 2011 Mar; 471(7336):17-8. PubMed ID: 21368796
[No Abstract] [Full Text] [Related]
16. Is pharma running out of brainy ideas?
Miller G
Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165
[No Abstract] [Full Text] [Related]
17. Drug development research: diabetes favored over cardiovascular disease?
Suckling K
Curr Opin Investig Drugs; 2009 Mar; 10(3):217-9. PubMed ID: 19333877
[No Abstract] [Full Text] [Related]
18. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
Perakslis ED; Van Dam J; Szalma S
Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001
[No Abstract] [Full Text] [Related]
19. Small study on industry trial sponsorship leads to big questions about quality and bias.
Twombly R
J Natl Cancer Inst; 2007 Jul; 99(13):988-90. PubMed ID: 17596566
[No Abstract] [Full Text] [Related]
20. Global pharmacogenomics: where is the research taking us?
Olivier C; Williams-Jones B
Glob Public Health; 2014; 9(3):312-24. PubMed ID: 24580118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
